We can’t show the full text here under this license. Use the link below to read it at the source.
Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy
Link between glucagon-like peptide-1 receptor agonist treatment and leftover stomach contents during upper digestive tract exams
AI simplified
Abstract
The proportion of gastric residue was statistically significantly higher in the GLP-1 receptor agonist treatment group at 5.4% compared to 0.49% in the non-treatment group (P = 0.004).
- GLP-1 receptor agonist () treatment is associated with increased gastric residue as observed during .
- The study included a matched pair case-control design with 1,128 individuals with diabetes, ultimately analyzing 205 matched pairs.
- Statistical analysis was performed using the McNemar test to compare gastric residue presence between treatment and non-treatment groups.
- Gastric residue was observed in 11 patients who received various GLP-1RA medications, including liraglutide, dulaglutide, and semaglutide.
AI simplified
Key numbers
5.4%
Increase in Gastric Residue Proportion
Proportion of gastric residue in -treated patients
0.49%
Gastric Residue in Non-treated Patients
Proportion of gastric residue in patients not treated with
205 pairs
Matched Patient Pairs
Number of matched pairs analyzed for gastric residue